search
Back to results

Evaluation of a Multidisciplinary Lifestyle Treatment for Inpatients With Mental Illness (MULTI+)

Primary Purpose

Mental Illness, Lifestyle

Status
Unknown status
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
MULTI+
Sponsored by
GGZ Centraal
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Mental Illness focused on measuring Inpatients, Implementation

Eligibility Criteria

16 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 16 years or older
  • Mentally ill inpatients
  • Receive care at the inpatient psychiatric wards of GGz Centraal where the MULTI+ will be implemented

Exclusion Criteria:

  • Limited knowledge or understanding of Dutch
  • If their psychiatric or physical condition hinders informed consent at the discretion of the relevant physician, nurses, or researcher

Sites / Locations

  • GGz CentraalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

TAU

MULTI+

Arm Description

Treatment as usual (TAU); consist mainly of pharmacological treatment and psychotherapy.

Lifestyle treatment

Outcomes

Primary Outcome Measures

QRISK3 score
Algorithm that estimates the probability of developing cardiovascular disease over the next 10 years by taking multiple risk factors into account.

Secondary Outcome Measures

Change in metabolic health: Waist circumference
waist circumference measured halfway between the iliac crest and lowest rib in standing position
Change in metabolic health: Systolic and diastolic blood pressure
Measured systolic and diastolic blood pressure (mmHg)
Change in metabolic Health:Lipids
Values in blood sample
Change in metabolic Health: HDL Cholesterol
Values in blood sample
Change in metabolic Health: triglycerides
Values in blood sample
Change in metabolic Health: Fasting glucose
Values in blood sample
Weight Change
Weight is measured to the nearest 0.1 kg.
Change in BMI
weight divided by height in meters squared
Change in medication use through daily defined doses (DDD)
Medication prescribed for cardiovascular health and diabetes, and psychotropic medication will be converted into daily defined doses (DDD) according the Anatomical Therapeutic Chemical Classification System from the World Health Organization (WHO). Medication data is obtained from patient files.
Change in psychosocial functioning: Adults
Measured by the Health of the Nations Outcomes Scale (HoNOS-12). All items are scored on a 5-point Likert scale, ranging from 0 (no problem) to 4 (severe problem).
Change in psychosocial functioning: Elderly
Measured by the Health of the Nations Outcomes Scale (HoNOS-65+). All items are scored on a 5-point Likert scale, ranging from 0 (no problem) to 4 (severe problem).
Change in psychosocial functioning: Adolescents
Measured by the Health of the Nations Outcomes Scale (HoNOSCA). All items are scored on a 5-point Likert scale, ranging from 0 (no problem) to 4 (severe problem).
Change in substance use
Measured by routine questions about smoking, alcohol use and soft drugs
Change in diet
Measured by a 24-hour dietary recall (24HR)
Change in dietary habits
Measured by the Three Factor Eating Questionnaire Revised 18-items (TFEQ-R18), which consists of 18 items on a 4 point measuring scale, measuring cognitive restraint, uncontrolled eating and emotional eating. Raw scale scores are transformed on a scale from 0-100 (raw score- lowest possible score/possible raw score range)*100).
Change in physical activity (PA): PaVs
Measured by the physical activity vital sign (PaVs). The PaVs is a two-item questionnaire, recommended as a brief way to routinely gain insight in physical activity levels. The PaVs can be used to assess whether the national activity guideline for aerobic activity are met in the context of health considerations (yes = 1, no = 0). Higher score means that the national activity guidelines are met.
Change in physical activity (PA): SIMPAQ
Measure by the Simple Physical activity Questionnaire (SIMPAQ). The SIMPAQ consists of five items (boxes), and participants are asked about time spent in bed (box 1), time sedentary, including naps (box 2), time spent walking (box 3), time spent exercising (box 4) and time spent in incidental activity, such as housekeeping (box 5). The total self-reported time spent on moderate-vigorous physical activity (MVPA) can be calculated by adding box 4 and 5.
Change in sleep (SCOPA-sleep)
Measured by the Scales for Outcomes in Parkinson's Disease - Sleep (SCOPA-Sleep). The SCOPA-Sleep is developed to evaluate night-time sleep and daytime sleepiness in a short and practical manner. The questionnaire enquires about the use of sleep medication and if so, which medication. It then uses 5 items to evaluate night-time sleep, 1 question inquiring overall quality of sleep followed by 6 items to evaluate daytime sleepiness on a 4 point Likert scale ranging from 0 (not at all) to 4 (a lot).
Change in psychopathology (BSI)
Measured by the Brief Symptom Inventory (BSI). The BSI comprises 53 items that reflect 9 symptom domains of psychopathology (somatization, obsessive compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation and psychoticism). Each item is rated on a 5-point scale of distress from 0 (not at all) to 4 (extremely).
Change in Quality of life (WHOQoL-Bref)
Measured by the World Health Organisation Quality of Life-BREF (WHOQoL-BREF). The four WHOQoL-BREF domains are measured through 24 domain-specific items: Physical health (7 items), Psychological (6 items), Social relations (3 items) and Environment (8 items) and two general health items. Item scores have various options but always range from 1 to 5, such as very poor to very good or not at all to extremely, and will be converted to domain scores (range from 4 to 20) based on the WHO guidelines. Higher score reflect a better quality of life.
Change in Quality of life (EQ-5D)
Measured by the EuroQol 5D (EQ-5D).The EQ-5D is a generic instrument that consists of 5 dimensions of health, with one item per dimension; mobility, selfcare, usual activities, pain/discomfort, and anxiety/depression. There are three levels of severity ranging from no issues to many issues. The index score are calculated ranging from 0 (worst quality of life) to 1 (perfect quality of life).
Change in meaning in life (MHC-SF)
Measured by the Mental Health Continuum - Short Form (MHC-SF). The MHC-SF measures positive mental health and consists of 14 items, representing feelings of well-being: Emotional well-being (three items), Psychological well-being (six items), and Social well-being (five items). Participants rate the frequency of these feelings in the past month on a 6-point Likert scale (never, once or twice a month, about once a week, two or three times a week, almost every day, every day).
Barriers and facilitators of the implementation of the MULTI+ (MIDI)
Measured by the Measurement Instrument for Determinants of the Innovation (MIDI). The MIDI is comprised of 28 items, divided into 4 scales measuring determinants associated with innovations (7 items), the user (11 items) and the organization (10 items). All items are scored on a 5-point Likert scale ranging from 1 (totally disagree) to 5 (totally agree). Items which ≥20% responds negatively (disagree/totally disagree) are considered barriers. Items which ≥80% respond positively (agree/totally agree) are considered facilitators.
Change in amount of adverse events
Institutional software in which employees register and categorize adverse events (e.g. aggression).
Change in motivation for behavioural regulation for physical activity
Measured by the Behavioural Regulation in Exercise Questionnaire (BREQ-2). The BREQ-2 is comprised of 19 items, divided into 5 scales measuring; Amotivation (item 5, 9 12, 19), External (item 1, 6, 11, 16), Identified (item 2, 7, 13), Introjected (item 3, 8, 14, 17), and Intrinsic (item 4, 10, 15, 18 ) regulations. The mean scores for each scale can be used as a multidimensional instrument, giving separate scores for each subscale.
Change in motivation for behavioural regulation for healthy diet
Based on the BREQ-2 as used in this study, the researchers devised a behavioural regulation diet questionnaire. All mentioning of "exercise" in the BREQ-2 has been replaced by referring to "(eat a) healthy diet". This questionnaire comprised of 19 items, divided into 5 scales measuring; Amotivation (item 5, 9 12, 19), External (item 1, 6, 11, 16), Identified (item 2, 7, 13), Introjected (item 3, 8, 14, 17), and Intrinsic (item 4, 10, 15, 18 ) regulations. The mean scores for each scale can be used as a multidimensional instrument, giving separate scores for each subscale.
Health Technology Assessment (HTA)
Cost-effectiveness will be investigated through calculation of the costs of treatment as usual as compared to costs of MULTI+

Full Information

First Posted
June 3, 2021
Last Updated
November 8, 2021
Sponsor
GGZ Centraal
Collaborators
Stichting tot steun VCVGZ, UMC Utrecht, Maastricht University, The Healthcare Innovation Centre
search

1. Study Identification

Unique Protocol Identification Number
NCT04922749
Brief Title
Evaluation of a Multidisciplinary Lifestyle Treatment for Inpatients With Mental Illness
Acronym
MULTI+
Official Title
Evaluation of the Implementation and Effectiveness of a Multidisciplinary Lifestyle Treatment for Inpatients With Mental Illness (MULTI+)
Study Type
Interventional

2. Study Status

Record Verification Date
June 2021
Overall Recruitment Status
Unknown status
Study Start Date
July 1, 2020 (Actual)
Primary Completion Date
September 1, 2022 (Anticipated)
Study Completion Date
September 1, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
GGZ Centraal
Collaborators
Stichting tot steun VCVGZ, UMC Utrecht, Maastricht University, The Healthcare Innovation Centre

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
People with mental illness (MI) have a reduced life expectancy compared to the general population, mostly attributable to somatic diseases caused by poor physical health. Modifiable "lifestyle factors" have been increasingly associated with the onset of somatic diseases in people with MI and refer to health behaviours such as physical activity (PA), diet, sleep and smoking behaviour. Despite the evidence demonstrating the efficacy of interventions aimed at improving lifestyle factors, there have not been many structural changes in routine clinical care for people with MI. Using a multidisciplinary, multicomponent approach, Deenik and colleagues (2019) were the first to find long-term positive effects in both mental and somatic health in a real-world inpatient setting for people with severe mental illness (SMI). They found improvements in metabolic health, psychosocial functioning and quality of life, and a reduction in the use of psychotropic medication. The authors urged to confirm and complement findings in scaled-up studies, and made several suggestions for improvement of the treatment and pragmatic research of implementation. In line with these previous recommendations the MULTI is being scaled-up into the MULTI+. This study investigates the implementation and effectiveness of a multidisciplinary lifestyle treatment for inpatients with mental illness (MULTI+).
Detailed Description
Study design and setting This study is a prospective open cohort stepped wedge cluster randomized trial with continuous recruitment. This study is being conducted at the inpatient psychiatric wards, covering approximately 750 places of residency in which approximately 2000 patients are treated annually, from the specialist mental healthcare organisation GGz Centraal (the Netherlands). The study uses a stepped-wedge clustered design. The psychiatric wards are divided into three clusters, based on their geographical locations. These clusters gradually implement MULTI+ in semi-annual steps, such that all clusters are exposed to the MULTI+ at the end of the study. The repeated measurements are conducted on ward-level, rather than individual patient level. Intervention MULTI+ is a multidisciplinary, multicomponent treatment which aims to improve lifestyle factors through a holistic lifestyle approach, by focusing on 10 core components. Core components refer to essential elements and activities that are necessary to achieve desired outcomes. The core components of MULTI+ are based on previous recommendations and existing literature. The core components of MULTI+ are routine daily structure and sleep, physical activity, attention to nutrition and eating habits, smoking cessation, multidisciplinary treatment, skills training, psychoeducation, critical review of obesogenic environment and existing policies, active participation of health care professionals (HCPs), and training of HCPs. The core components are co-designed and tailored to the ward and patient population, because of the large heterogeneity in patient characteristics and varying access to facilities and staffing. Analyses To measure the intervention effect, linear mixed models will be used for continuous outcome measures and logistic mixed models for dichotomous outcome measures. In each model, the intervention effect will be estimated as the difference between the postintervention and preintervention levels of the outcome after adjusting for time as a categorical variable. All models will be corrected for group differences at baseline and the baseline differences of the outcome measures concerned (to account for regression to the mean).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mental Illness, Lifestyle
Keywords
Inpatients, Implementation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Model Description
Prospective open cohort stepped wedge cluster randomized trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
846 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
TAU
Arm Type
No Intervention
Arm Description
Treatment as usual (TAU); consist mainly of pharmacological treatment and psychotherapy.
Arm Title
MULTI+
Arm Type
Experimental
Arm Description
Lifestyle treatment
Intervention Type
Behavioral
Intervention Name(s)
MULTI+
Intervention Description
MULTI+ is a multidisciplinary, multicomponent treatment which aims to improve lifestyle factors through a holistic lifestyle approach, by focusing on 10 core components. The MULTI+ will be integrated into daily treatment to promote uptake and sustainability.
Primary Outcome Measure Information:
Title
QRISK3 score
Description
Algorithm that estimates the probability of developing cardiovascular disease over the next 10 years by taking multiple risk factors into account.
Time Frame
4 measurements semi-annually over a period of 24 months
Secondary Outcome Measure Information:
Title
Change in metabolic health: Waist circumference
Description
waist circumference measured halfway between the iliac crest and lowest rib in standing position
Time Frame
4 measurements semi-annually over a period of 24 months
Title
Change in metabolic health: Systolic and diastolic blood pressure
Description
Measured systolic and diastolic blood pressure (mmHg)
Time Frame
4 measurements semi-annually over a period of 24 months
Title
Change in metabolic Health:Lipids
Description
Values in blood sample
Time Frame
4 measurements semi-annually over a period of 24 months
Title
Change in metabolic Health: HDL Cholesterol
Description
Values in blood sample
Time Frame
4 measurements semi-annually over a period of 24 months
Title
Change in metabolic Health: triglycerides
Description
Values in blood sample
Time Frame
4 measurements semi-annually over a period of 24 months
Title
Change in metabolic Health: Fasting glucose
Description
Values in blood sample
Time Frame
4 measurements semi-annually over a period of 24 months
Title
Weight Change
Description
Weight is measured to the nearest 0.1 kg.
Time Frame
4 measurements semi-annually over a period of 24 months
Title
Change in BMI
Description
weight divided by height in meters squared
Time Frame
4 measurements semi-annually over a period of 24 months
Title
Change in medication use through daily defined doses (DDD)
Description
Medication prescribed for cardiovascular health and diabetes, and psychotropic medication will be converted into daily defined doses (DDD) according the Anatomical Therapeutic Chemical Classification System from the World Health Organization (WHO). Medication data is obtained from patient files.
Time Frame
4 measurements semi-annually over a period of 24 months
Title
Change in psychosocial functioning: Adults
Description
Measured by the Health of the Nations Outcomes Scale (HoNOS-12). All items are scored on a 5-point Likert scale, ranging from 0 (no problem) to 4 (severe problem).
Time Frame
4 measurements semi-annually over a period of 24 months
Title
Change in psychosocial functioning: Elderly
Description
Measured by the Health of the Nations Outcomes Scale (HoNOS-65+). All items are scored on a 5-point Likert scale, ranging from 0 (no problem) to 4 (severe problem).
Time Frame
4 measurements semi-annually over a period of 24 months
Title
Change in psychosocial functioning: Adolescents
Description
Measured by the Health of the Nations Outcomes Scale (HoNOSCA). All items are scored on a 5-point Likert scale, ranging from 0 (no problem) to 4 (severe problem).
Time Frame
4 measurements semi-annually over a period of 24 months
Title
Change in substance use
Description
Measured by routine questions about smoking, alcohol use and soft drugs
Time Frame
4 measurements semi-annually over a period of 24 months
Title
Change in diet
Description
Measured by a 24-hour dietary recall (24HR)
Time Frame
4 measurements semi-annually over a period of 24 months
Title
Change in dietary habits
Description
Measured by the Three Factor Eating Questionnaire Revised 18-items (TFEQ-R18), which consists of 18 items on a 4 point measuring scale, measuring cognitive restraint, uncontrolled eating and emotional eating. Raw scale scores are transformed on a scale from 0-100 (raw score- lowest possible score/possible raw score range)*100).
Time Frame
4 measurements semi-annually over a period of 24 months
Title
Change in physical activity (PA): PaVs
Description
Measured by the physical activity vital sign (PaVs). The PaVs is a two-item questionnaire, recommended as a brief way to routinely gain insight in physical activity levels. The PaVs can be used to assess whether the national activity guideline for aerobic activity are met in the context of health considerations (yes = 1, no = 0). Higher score means that the national activity guidelines are met.
Time Frame
4 measurements semi-annually over a period of 24 months
Title
Change in physical activity (PA): SIMPAQ
Description
Measure by the Simple Physical activity Questionnaire (SIMPAQ). The SIMPAQ consists of five items (boxes), and participants are asked about time spent in bed (box 1), time sedentary, including naps (box 2), time spent walking (box 3), time spent exercising (box 4) and time spent in incidental activity, such as housekeeping (box 5). The total self-reported time spent on moderate-vigorous physical activity (MVPA) can be calculated by adding box 4 and 5.
Time Frame
4 measurements semi-annually over a period of 24 months
Title
Change in sleep (SCOPA-sleep)
Description
Measured by the Scales for Outcomes in Parkinson's Disease - Sleep (SCOPA-Sleep). The SCOPA-Sleep is developed to evaluate night-time sleep and daytime sleepiness in a short and practical manner. The questionnaire enquires about the use of sleep medication and if so, which medication. It then uses 5 items to evaluate night-time sleep, 1 question inquiring overall quality of sleep followed by 6 items to evaluate daytime sleepiness on a 4 point Likert scale ranging from 0 (not at all) to 4 (a lot).
Time Frame
4 measurements semi-annually over a period of 24 months
Title
Change in psychopathology (BSI)
Description
Measured by the Brief Symptom Inventory (BSI). The BSI comprises 53 items that reflect 9 symptom domains of psychopathology (somatization, obsessive compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation and psychoticism). Each item is rated on a 5-point scale of distress from 0 (not at all) to 4 (extremely).
Time Frame
4 measurements semi-annually over a period of 24 months
Title
Change in Quality of life (WHOQoL-Bref)
Description
Measured by the World Health Organisation Quality of Life-BREF (WHOQoL-BREF). The four WHOQoL-BREF domains are measured through 24 domain-specific items: Physical health (7 items), Psychological (6 items), Social relations (3 items) and Environment (8 items) and two general health items. Item scores have various options but always range from 1 to 5, such as very poor to very good or not at all to extremely, and will be converted to domain scores (range from 4 to 20) based on the WHO guidelines. Higher score reflect a better quality of life.
Time Frame
4 measurements semi-annually over a period of 24 months
Title
Change in Quality of life (EQ-5D)
Description
Measured by the EuroQol 5D (EQ-5D).The EQ-5D is a generic instrument that consists of 5 dimensions of health, with one item per dimension; mobility, selfcare, usual activities, pain/discomfort, and anxiety/depression. There are three levels of severity ranging from no issues to many issues. The index score are calculated ranging from 0 (worst quality of life) to 1 (perfect quality of life).
Time Frame
4 measurements semi-annually over a period of 24 months
Title
Change in meaning in life (MHC-SF)
Description
Measured by the Mental Health Continuum - Short Form (MHC-SF). The MHC-SF measures positive mental health and consists of 14 items, representing feelings of well-being: Emotional well-being (three items), Psychological well-being (six items), and Social well-being (five items). Participants rate the frequency of these feelings in the past month on a 6-point Likert scale (never, once or twice a month, about once a week, two or three times a week, almost every day, every day).
Time Frame
4 measurements semi-annually over a period of 24 months
Title
Barriers and facilitators of the implementation of the MULTI+ (MIDI)
Description
Measured by the Measurement Instrument for Determinants of the Innovation (MIDI). The MIDI is comprised of 28 items, divided into 4 scales measuring determinants associated with innovations (7 items), the user (11 items) and the organization (10 items). All items are scored on a 5-point Likert scale ranging from 1 (totally disagree) to 5 (totally agree). Items which ≥20% responds negatively (disagree/totally disagree) are considered barriers. Items which ≥80% respond positively (agree/totally agree) are considered facilitators.
Time Frame
4 measurements semi-annually over a period of 24 months
Title
Change in amount of adverse events
Description
Institutional software in which employees register and categorize adverse events (e.g. aggression).
Time Frame
24 months
Title
Change in motivation for behavioural regulation for physical activity
Description
Measured by the Behavioural Regulation in Exercise Questionnaire (BREQ-2). The BREQ-2 is comprised of 19 items, divided into 5 scales measuring; Amotivation (item 5, 9 12, 19), External (item 1, 6, 11, 16), Identified (item 2, 7, 13), Introjected (item 3, 8, 14, 17), and Intrinsic (item 4, 10, 15, 18 ) regulations. The mean scores for each scale can be used as a multidimensional instrument, giving separate scores for each subscale.
Time Frame
4 measurements semi-annually over a period of 24 months
Title
Change in motivation for behavioural regulation for healthy diet
Description
Based on the BREQ-2 as used in this study, the researchers devised a behavioural regulation diet questionnaire. All mentioning of "exercise" in the BREQ-2 has been replaced by referring to "(eat a) healthy diet". This questionnaire comprised of 19 items, divided into 5 scales measuring; Amotivation (item 5, 9 12, 19), External (item 1, 6, 11, 16), Identified (item 2, 7, 13), Introjected (item 3, 8, 14, 17), and Intrinsic (item 4, 10, 15, 18 ) regulations. The mean scores for each scale can be used as a multidimensional instrument, giving separate scores for each subscale.
Time Frame
4 measurements semi-annually over a period of 24 months
Title
Health Technology Assessment (HTA)
Description
Cost-effectiveness will be investigated through calculation of the costs of treatment as usual as compared to costs of MULTI+
Time Frame
24 months
Other Pre-specified Outcome Measures:
Title
Process evaluation - Change in RE-AIM domains
Description
The process evaluation is conducted using the RE-AIM framework (RE-AIM). Reach, Efficacy, Adoption, Implementation and Maintenance will be assessed continuously throughout the study. There are no scores attached to the domains, rather, change is evaluated.
Time Frame
24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 16 years or older Mentally ill inpatients Receive care at the inpatient psychiatric wards of GGz Centraal where the MULTI+ will be implemented Exclusion Criteria: Limited knowledge or understanding of Dutch If their psychiatric or physical condition hinders informed consent at the discretion of the relevant physician, nurses, or researcher
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jeroen Deenik, Dr.
Phone
+31622049524
Email
j.deenik@ggzcentraal.nl
First Name & Middle Initial & Last Name or Official Title & Degree
Myrthe van Schothorst, MSc
Phone
+3182648117
Email
m.vanschothorst@ggzcentraal.nl
Facility Information:
Facility Name
GGz Centraal
City
Amersfoort
State/Province
Utrecht
ZIP/Postal Code
3818 EW
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jeroen Deenik, Dr.
Phone
+31622049534
Email
j.deenik@ggzcentraal.nl

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
28237639
Citation
Hjorthoj C, Sturup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017 Apr;4(4):295-301. doi: 10.1016/S2215-0366(17)30078-0. Epub 2017 Feb 22. Erratum In: Lancet Psychiatry. 2017 Sep;4(9):e19.
Results Reference
background
PubMed Identifier
28498599
Citation
Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P, Thapa-Chhetri N, Fornaro M, Gallicchio D, Collantoni E, Pigato G, Favaro A, Monaco F, Kohler C, Vancampfort D, Ward PB, Gaughran F, Carvalho AF, Stubbs B. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017 Jun;16(2):163-180. doi: 10.1002/wps.20420. Erratum In: World Psychiatry. 2018 Feb;17 (1):120.
Results Reference
background
PubMed Identifier
31169897
Citation
Deenik J, Czosnek L, Teasdale SB, Stubbs B, Firth J, Schuch FB, Tenback DE, van Harten PN, Tak ECPM, Lederman O, Ward PB, Hendriksen IJM, Vancampfort D, Rosenbaum S. From impact factors to real impact: translating evidence on lifestyle interventions into routine mental health care. Transl Behav Med. 2020 Oct 8;10(4):1070-1073. doi: 10.1093/tbm/ibz067.
Results Reference
background
PubMed Identifier
32700302
Citation
Deenik J, Tenback DE, Tak ECPM, Hendriksen IJM, van Harten PN. [Thinking inside the box: improving the lifestyle of inpatients with severe mental illness]. Tijdschr Psychiatr. 2020;62(7):564-574. Dutch.
Results Reference
background
PubMed Identifier
31324560
Citation
Firth J, Siddiqi N, Koyanagi A, Siskind D, Rosenbaum S, Galletly C, Allan S, Caneo C, Carney R, Carvalho AF, Chatterton ML, Correll CU, Curtis J, Gaughran F, Heald A, Hoare E, Jackson SE, Kisely S, Lovell K, Maj M, McGorry PD, Mihalopoulos C, Myles H, O'Donoghue B, Pillinger T, Sarris J, Schuch FB, Shiers D, Smith L, Solmi M, Suetani S, Taylor J, Teasdale SB, Thornicroft G, Torous J, Usherwood T, Vancampfort D, Veronese N, Ward PB, Yung AR, Killackey E, Stubbs B. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry. 2019 Aug;6(8):675-712. doi: 10.1016/S2215-0366(19)30132-4. Epub 2019 Jul 16. No abstract available.
Results Reference
background
PubMed Identifier
32931092
Citation
Firth J, Solmi M, Wootton RE, Vancampfort D, Schuch FB, Hoare E, Gilbody S, Torous J, Teasdale SB, Jackson SE, Smith L, Eaton M, Jacka FN, Veronese N, Marx W, Ashdown-Franks G, Siskind D, Sarris J, Rosenbaum S, Carvalho AF, Stubbs B. A meta-review of "lifestyle psychiatry": the role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders. World Psychiatry. 2020 Oct;19(3):360-380. doi: 10.1002/wps.20773.
Results Reference
background
PubMed Identifier
26768358
Citation
Suetani S, Rosenbaum S, Scott JG, Curtis J, Ward PB. Bridging the gap: What have we done and what more can we do to reduce the burden of avoidable death in people with psychotic illness? Epidemiol Psychiatr Sci. 2016 Jun;25(3):205-10. doi: 10.1017/S2045796015001043. Epub 2016 Jan 15.
Results Reference
background
PubMed Identifier
31507466
Citation
Firth J, Ward PB, Stubbs B. Editorial: Lifestyle Psychiatry. Front Psychiatry. 2019 Aug 26;10:597. doi: 10.3389/fpsyt.2019.00597. eCollection 2019. No abstract available.
Results Reference
background
PubMed Identifier
25662947
Citation
Hemming K, Haines TP, Chilton PJ, Girling AJ, Lilford RJ. The stepped wedge cluster randomised trial: rationale, design, analysis, and reporting. BMJ. 2015 Feb 6;350:h391. doi: 10.1136/bmj.h391. No abstract available.
Results Reference
background
PubMed Identifier
29884236
Citation
Koorts H, Eakin E, Estabrooks P, Timperio A, Salmon J, Bauman A. Implementation and scale up of population physical activity interventions for clinical and community settings: the PRACTIS guide. Int J Behav Nutr Phys Act. 2018 Jun 8;15(1):51. doi: 10.1186/s12966-018-0678-0.
Results Reference
background
PubMed Identifier
35361168
Citation
den Bleijker NM, van Schothorst MME, Hendriksen IJM, Cahn W, de Vries NK, van Harten PN, Deenik J. Effectiveness and implementation of a multidisciplinary lifestyle focused approach in the treatment of inpatients with mental illness (MULTI +): a stepped wedge study protocol. BMC Psychiatry. 2022 Mar 31;22(1):230. doi: 10.1186/s12888-022-03801-w.
Results Reference
derived

Learn more about this trial

Evaluation of a Multidisciplinary Lifestyle Treatment for Inpatients With Mental Illness

We'll reach out to this number within 24 hrs